Blood Component Removal (Apheresis)

Subscribe to Selected New Research on Blood Component Removal

1209 relevant articles (160 outcomes, 137 trials/studies) found for this Therapy

Description: Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.

Also Known As:

Apheresis; Pheresis; Aphereses; Blood Component Removals; Component Removal, Blood; Component Removals, Blood; Phereses; Removal, Blood Component; Removals, Blood Component

Relationship Network

Therapy Context: Research Results

Therapeutics: 5195

Blood Component Removal: 1209

Plasmapheresis: 2594

Bone Marrow Purging: 104

Cytapheresis

Leukocyte Reduction Procedures

Experts

1.	Kanekura, Takuro: 8 articles (06/2006 - 08/2002)
2.	Kanzaki, Tamotsu: 8 articles (06/2006 - 08/2002)
3.	Maruyama, Ikuro: 7 articles (06/2006 - 08/2002)
4.	Saniabadi, Abby R: 7 articles (04/2004 - 06/2002)
5.	Nakamura, Tsukasa: 6 articles (01/2005 - 01/2003)
6.	Koide, Hikaru: 6 articles (01/2005 - 01/2003)
7.	Löfberg, Robert: 5 articles (08/2008 - 11/2005)
8.	Suzuki, Yasuo: 5 articles (06/2007 - 01/2003)
9.	Sandborn, William J: 4 articles (08/2008 - 12/2005)
10.	Kawahara, Koichi: 4 articles (06/2006 - 06/2005)

Related Diseases

1.	Ulcerative Colitis 11/28/2005 - "Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis." 01/01/2008 - "BACKGROUND: Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC)" 10/01/2002 - "Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis." 05/01/1998 - "We have already reported that leukocyte apheresis using a centrifugal procedure was effective for patients with corticosteroid-resistant ulcerative colitis after conducting a pilot study in 14 patients" 08/01/2008 - "Open-label studies and clinical experience in Japan and Europe have suggested that granulocyte/monocyte apheresis is safe and effective in treating ulcerative colitis" Get all the results and reference details, order at left...
2.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/01/2001 - "CONCLUSIONS: At present, LDL-apheresis is the most effective and safe therapeutic approach to the treatment of homozygous, heterozygous and double heterozygous familial hypercholesterolemia." 08/01/2003 - "The present data demonstrate that treatment with LDL apheresis of patients suffering from familial hypercholesterolemia resistant to maximum conservative therapy is very effective and safe even in long-term application." 02/01/2002 - "The present data demonstrate that treatment with LDL apheresis of patients suffering from familial hypercholesterolemia resistant to maximum conservative therapy is very effective and safe even in long-term application." 09/01/1999 - "The present data demonstrate that treatment with LDL-apheresis of patients suffering from familial hypercholesterolemia resistant to maximum conservative therapy is very effective and safe, even in long-term application." 02/01/1997 - "The present data clearly demonstrate that treatment with LDL apheresis of patients suffering from familial hypercholesterolemia, resistant to maximum conservative therapy, is very effective and safe, even in long-term application." Get all the results and reference details, order at left...
3.	Coronary Artery Disease (Coronary Atherosclerosis) 08/01/1997 - "Studies outside the United States have found therapy with LDL apheresis to be associated with a favorable clinical outcome including improved myocardial perfusion, but variable regression of coronary artery disease (CAD)" 08/01/1997 - "LDL apheresis is effective in the prevention of the progression of coronary atherosclerosis" 01/01/2004 - "The aim of the present study was to investigate the effects lipid lowering by LDL apheresis on platelet function in patients with coronary artery disease" 08/01/2003 - "Similarly, in the studies with a angiographic parameter, coronary atherosclerosis was suppressed or regressed by LDL apheresis" 10/01/1999 - "Several angiographic studies have demonstrated that regular LDL apheresis therapy had favorable effects on the progression of coronary atherosclerosis" Get all the results and reference details, order at left...
4.	Hyperlipidemias (Hyperlipidemia) 04/01/1996 - "The present data clearly demonstrate that treatment with LDL apheresis in patients suffering from severe familial hyperlipidemia, resistant to maximum conservative therapy, is very effective and safe even over long periods of time." 08/01/2001 - "The published data clearly demonstrate that treatment with LDL-apheresis in patients suffering from severe hyperlipidemia refractory to maximum conservative therapy is effective and safe in long-term application." 08/01/2007 - "After treatment with our new system, the acute mean LDL-C reduction was 97% in the apheresis plasma of hyperlipidemia patients" 02/01/2003 - "Micro- and macrocirculatory effects of apheresis in patients with familial hyperlipidemia." 08/01/2001 - "LDL apheresis may be worth trying, particularly for patients complicated by hyperlipemia." Get all the results and reference details, order at left...
5.	Hypercholesterolemia 09/01/2002 - "CONCLUSIONS: LDL apheresis using the DALI system is highly efficacious for the treatment of hypercholesterolemia" 01/01/1994 - "Biological efficacy of LDL apheresis in major hypercholesterolemia]" 12/01/1995 - "These findings suggest that LDL-apheresis, when performed before and after PTCA, is effective in preventing restenosis of coronary artery lesions in patients with CHD and hypercholesterolemia." 01/01/2002 - "LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia." 12/01/2007 - "Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: a prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure." Get all the results and reference details, order at left...
315 Diseases and 1209 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Lipoproteins (Lipoprotein)
2.	Dextran Sulfate
3.	Fibrinogen (Factor I)
4.	Cholesterol
5.	Heparin (Liquaemin)
6.	Lipoprotein(a)
7.	salicylhydroxamic acid (SHAM)
8.	Cyclophosphamide (Cytoxan)
9.	LDL Cholesterol
10.	Cyclosporine (Ciclosporin)
299 Drugs and Important Bio-Agents and 574 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Plasma Exchange
4.	Aftercare (After-Treatment)
5.	Plasmapheresis
48 Therapies and Procedures and 237 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>